LNC Bio recorded a consolidated operating profit of KRW 8.58 billion in the second quarter of 2026, successfully swinging to the black compared to the same period last year.

According to a regulatory filing on the 11th, LNC Bio's Q2 consolidated sales stood at KRW 38.7885 billion, surging 28.0% from the previous quarter (KRW 30.295 billion) and 88.4% year-on-year (KRW 20.581 billion). Operating profit for the same period was KRW 8.58 billion, up 43.0% from the previous quarter (KRW 5.999 billion). This marks a dramatic turnaround to profitability compared to an operating loss of KRW 245 million recorded in the same period last year.

However, despite the strong operating profit, the company reported a net loss of KRW 28.123 billion in the current period, swinging back to a loss from a net profit of KRW 2.726 billion in the previous quarter. Compared to the same period last year (net loss of KRW 14.276 billion), the loss widened further. The net loss attributable to owners of the parent company also amounted to KRW 27.999 billion.

Loss from continuing operations before income tax expenses was KRW 7.116 billion, turning to a loss from the previous quarter's profit of KRW 3.012 billion. However, compared to the same period last year (loss of KRW 14.032 billion), the loss narrowed by 49.3%.

On a cumulative basis for the first half of this year, the company achieved sales of KRW 69.08 billion (up 80.6% year-on-year) and an operating profit of KRW 14.579 billion (swinging to profit from an operating loss of KRW 435 million in the same period last year). Meanwhile, the cumulative net loss for the first half stood at KRW 25.397 billion.

These figures are based on preliminary consolidated financial statements prepared in accordance with the Korean International Financial Reporting Standards (K-IFRS). The company stated, "This is an internal settlement figure that has not been reviewed by an external auditor, and may be subject to change following future audit and review results."